Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier

Oncology Reports

Volumn 18, Issue 1, 2007, Pages 279-285

  Kong, Jing ^a   Diao, Zhenyu ^b   Deng, Xiaozhao ^c   Zhong, Hui ^a   Yao, Wenjuan ^b   Hu, Xuefang ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING NORMAL UNIVERSITY   (China)

^c Huadong Research Institute for Medicine and Biotechniques   (China)

Author keywords

Cellular immunity; Epitope; Growth factor receptor; HBc particles; Hepatocellular carcinoma; Humoral immunity; Ligand; Tumor associated antigen

Indexed keywords

ALPHA FETOPROTEIN; EPITOPE; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; PEPTIDE FRAGMENT; TELOMERASE; TERT PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE MODEL; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; SECRETION; TUMOR CELL LINE;

ALPHA-FETOPROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE;

EID: 34548040710     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.1.279     Document Type: Article

References (38)

1. Bain I and McMaster P: Benign and malignant liver tumours. Surgery 15: 169-174, 1997. (Pubitemid 127108643)
2. Duvoux C: Epidemiology and diagnosis of HCC in cirrhosis. Ann Chir 52: 511-517, 1998.
3. Badvie S: Hepatocellular carcinoma. Postgrad Med J 76: 4-11, 2000.
4. Lin SM, Lin CJ, Lin CC, Hsu CW and Chen YC: Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54: 1151-1156, 2005.
5. Greten TF and Jaffee EM: Cancer vaccines. J Clin Oncol 17: 1047-1060, 1999. (Pubitemid 29109339)
6. Bottcher B, Wynne SA and Crowther RA: Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature 386: 88-91, 1997. (Pubitemid 27130926)
7. Wu L, Diao Z, Deng X, Gao J, Zhou Z, Liu Y and Wang Y: DNA vaccine against Taenia solium cysticercosis expressed as a modified hepatitis B virus core particle containing three epitopes shared by Taenia crassiceps and Taenia solium. J Nanosci Nanotechnol 5: 1204-1210, 2005. (Pubitemid 44502130)
8. Borisova G, Arya B, Dislers A, Borschukova O, Tsibinogin V, Skrastina D, Eldarov MA, Pumpens P, Skryabin KG and Grens E: Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen. J Virol 67: 3696-3701, 1993. (Pubitemid 23143759)
9. Fehr T, Skrastina D, Pumpens P and Zinkernagel RM: T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci USA 95: 9477-9481, 1998. (Pubitemid 28506256)
10. Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA and Economou JS: Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 59: 3064-3067, 1999. (Pubitemid 29316002)
11. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH and Economou JS: T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166: 5300-5308, 2001. (Pubitemid 32280749)
12. + cells in patients with hepatocellular carcinoma. J Hepatol 40: 102-109, 2004.
13. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA and Kosmatopoulos K: Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10 and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169: 575-580, 2002. (Pubitemid 34686181)
14. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL and Yu JS: HER-2, gp100 and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64: 4980-4986, 2004. (Pubitemid 38924546)
15. Huang Q, Zhang X, Wang H, Yan B, Kirkpatrick J, Dewhrist MW and Li CY: A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 10: 1439-1445, 2004. (Pubitemid 38365239)
16. Gorbunova V, Seluanov A and Pereira-Smith OM: Evidence that high telomerase activity may induce a senescent-like growth arrest in human fibroblasts. J Biol Chem 278: 7692-7698, 2003.
17. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF and Chen SY: Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9: 4743-4755, 2003. (Pubitemid 37323277)
18. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL and Nadler LM: Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 7: 3343-3348, 2001. (Pubitemid 33069964)
19. Adjei AA and Hidalgo M: Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 23: 5386-5403, 2005. (Pubitemid 46206992)
20. Rowinsky EK: Signal events: cell signal transduction and its inhibition in cancer. Oncologist 8: 5-17, 2003.
21. Ren C, Li J and Zhao R: In vitro and in vivo experiment of transduction of reporter gene into tumors by E5 gene delivery system. Zhonghua Yi Xue Za Zhi 81: 1113-1117, 2001.
22. Liu X, Tian P, Yu Y, Yao M, Cao X and Gu J: Enhanced antitumor effect of EGF R-targeted p21WAF-1 and GM-CSF gene transfer in the established murine hepatoma by peritumoral injection. Cancer Gene Ther 9: 100-108, 2002. (Pubitemid 34052859)
23. Wang YS, Ma XL, Qi TG, Liu XD, Meng YS and Guan GJ: Downregulation of alpha-fetoprotein siRNA inhibits proliferation of SMMC-7721 cells. World J Gastroenterol 11: 6053-6055, 2005.
24. Xiao J, Chen HS, Fei R, Cong X, Wang LP, Wang Y, Jiang D, Wei L and Wang Y: Expression of MAGE-A1 mRNA is associated with gene hypomethylation in hepatocarcinoma cell lines. J Gastroenterol 40: 716-721, 2005. (Pubitemid 41349083)
25. Du QY, Wang XB, Chen XJ, Zheng W and Wang SQ: Antitumor mechanism of antisense cantide targeting human telomerase reverse transcriptase. World J Gastroenterol 9: 2030-2035, 2003. (Pubitemid 37168437)
26. Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Yang HY, Juang SH and Whang-Peng J: Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA- A*2402 late-stage colo-rectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 10: 2645-2651, 2004.
27. Twentyman PR and Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285, 1987. (Pubitemid 17158816)
28. Schodel F, Peterson D, Hughes J, Wirtz R and Milich D: Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes. J Biotechnol 44: 91-96, 1996. (Pubitemid 26056566)
29. Schodel F, Kelly S, Tinge S, Hopkins S, Peterson D, Milich D and Curtiss R III: Hybrid hepatitis B virus core antigen as a vaccine carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal immunization. Adv Exp Med Biol 397: 15-21, 1996. (Pubitemid 26066555)
30. Murray K and Shiau AL: The core antigen of hepatitis B virus as a carrier for immunogenic peptides. Biol Chem 380: 277-283, 1999. (Pubitemid 29145940)
31. Milich DR and McLachlan A: The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234: 1398-1401, 1986. (Pubitemid 17210220)
32. Schodel F, Moriarty AM, Peterson DL, Zheng JA, Hughes JL, Will H, Leturcq DJ, McGee JS and Milich DR: The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol 66: 106-114, 1992.
33. Korzeniewski C and Callewaert DM: An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64: 313-320, 1983. (Pubitemid 14243095)
34. Decker T and Lohmann-Matthes ML: A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115: 61-69, 1988.
35. Boehm U, Klamp T, Groot M and Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol 15: 749-795, 1997.
36. Kammula US, Marincola FM and Rosenberg SA: Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 92: 1336-1344, 2000. (Pubitemid 30660594)
37. Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC and Kaumaya PT: A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 170: 4242-4253, 2003. (Pubitemid 36428191)
38. Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D and Jaffee EM: The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 61: 880-883, 2001. (Pubitemid 32174395)